Is alectinib the new first line therapy in ALK-rearranged advanced non-small cell lung cancer?

Παρόμοια τεκμήρια

• First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
  ανά: Addeo, Alfredo, κ.ά.
  Έκδοση: (2018)
• ALK on my mind: alectinib takes an early lead in managing intracranial disease in non-small cell lung cancer with ALK rearrangements
  ανά: Tran, Phu N., κ.ά.
  Έκδοση: (2017)
• Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France
  ανά: Sivignon, Marine, κ.ά.
  Έκδοση: (2020)
• Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers
  ανά: Wei, Jiacong, κ.ά.
  Έκδοση: (2018)
• Alectinib can replace crizotinib as standard first-line therapy for ALK-positive lung cancer
  ανά: Uemura, Takehiro, κ.ά.
  Έκδοση: (2017)